OncoDNA, located in Gosselies, Belgium, has landed €19 million Series B funding. The healthtech startup, founded in 2012, is a leader in personalised molecular analysis for cancer patients. OncoDNA’s technology assists medical doctors in determining a treatment path and provides improved monitoring of tumour evolution in patients. With this round of funding secured, the startup has big plans.
OncoDNA is in the process of developing software which provides oncology clinical decision support. This technology will aid molecular laboratories, healthcare proffesionals and the pharma industry become more efficient in the areas of research and clinical practice.
Led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank, with the support of SFPI-FPIM, the funding will support rapid international growth, hiring initiatives and software development.